【24h】

USE OF AMBR250 AS A SMALL SCALE MODEL FOR MANUFACTURING-SCALE SINGLE-USE BIOREACTORS

机译:使用AMBR250作为制造单一用途生物反应器的小规模模型

获取原文
获取原文并翻译 | 示例

摘要

Quality by Design (QbD) has become an integral part of biopharmaceutical process development and manufacturing. To gain the enhanced process understanding required by QbD, a well-designed small scale model that accurately predicts behavior at manufacturing scale is essential. This process understanding should ideally be achieved with rapid, efficient experimentation to decrease both the time and cost required for development. The ambr250 automated microscale bioreactor system has the potential to address all of these challenges. By embedding the ambr250 into the upstream process development workflow, throughput can be dramatically increased allowing for greater exploration of parameter operating ranges and more complete process understanding. However, the value of such microscale technologies hinges on their ability to accurately mimic manufacturing scale. We embarked on a study to demonstrate the applicability of the ambr250 (250 mL) as a small scale model for a 2000-L single-use bioreactor (SUB). We evaluated consistency of cell culture process performance from the ambr250 to 2000-L SUB scale along with intermediate scales such as our legacy small scale model (3-L glass stirred-tank reactors) and 50-L to 1000-L SUBs. Scalability was assessed using two monoclonal antibody molecules expressed from different CHO hosts (CHO K1 and DG44) and cultivated in different media platforms (chemically-defined and yeastolate-containing) to ensure broad applicability of the small scale model. Engineering principles were applied to develop appropriate agitation and gassing strategies at each scale to ensure comparability, with a power input based scaling strategy performing the best. Based on both univariate and multivariate data analysis methods the ambr250 behaved comparably to both our legacy small scale model and the SUBs for the assets evaluated. Areas of focus to further refine the ambr250 as a small scale model have also been identified.
机译:设计质量(QbD)已成为生物制药过程开发和制造的组成部分。为了获得QbD所需的增强的过程理解,设计良好的小规模模型可以准确预测制造规模的行为,这一点至关重要。理想情况下,应该通过快速,有效的实验来实现对过程的理解,以减少开发所需的时间和成本。 ambr250自动化微型生物反应器系统具有解决所有这些挑战的潜力。通过将ambr250嵌入上游过程开发工作流程,可以显着提高吞吐量,从而可以更深入地研究参数操作范围和更全面的过程理解。但是,这种微型技术的价值取决于它们精确模拟制造规模的能力。我们着手进行一项研究,以证明ambr250(250 mL)作为2000 L一次性生物反应器(SUB)的小规模模型的适用性。我们评估了从ambr250到2000 L SUB规模以及中等规模(如我们的旧式小规模模型(3 L玻璃搅拌釜反应器)和50 L到1000 L SUBs)的细胞培养过程性能的一致性。使用从不同CHO宿主表达的两种单克隆抗体分子(CHO K1和DG44)评估可扩展性,并在不同的培养基平台(化学成分确定且含酵母酸盐)中进行培养,以确保小规模模型的广泛适用性。工程原理被应用于在每个规模上开发适当的搅拌和充气策略以确保可比性,其中基于功率输入的缩放策略表现最佳。基于单变量和多变量数据分析方法,ambr250的性能与我们的传统小规模模型和所评估资产的SUB相当。还确定了进一步完善ambr250作为小规模模型的重点领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号